SCHEMBL3352620

SCHEMBL3352620

Cc1nc2ccccn2c1-c1nc(C2(c3ccc(C(=O)Nc4ccccc4N)cc3)CCCC2)sc1C

nearest known ligand 0.51

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 15/20 0.51
CDK4 P11802 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3353718 0.97 HDAC1 (0.52) HDAC1CDK4CCNE1CDK2
SCHEMBL199437 0.93 HDAC1 (0.49) HDAC1
SCHEMBL3352579 0.89 HDAC1 (0.49) HDAC1CDK4CCNE1CDK2
SCHEMBL3350719 0.88 AKT1 (0.39) CDK4CCNE1CDK2
SCHEMBL3357440 0.87 HDAC1 (0.49) HDAC1
SCHEMBL197274 0.86 HDAC1 (0.54) HDAC1CDK4CCNE1CDK2
SCHEMBL3348291 0.84 AKT1 (0.38) HDAC1CDK4CCNE1CDK2
SCHEMBL3357410 0.83 HDAC1 (0.51) HDAC1
SCHEMBL196976 0.82 HDAC1 (0.56) HDAC1CDK4CCNE1CDK2
SCHEMBL197516 0.80 GAA (0.39) HDAC1CDK4CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC1 1/4885CDK4 276/4885CCNE1 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.